What retatrutide amounts did study doctors give?

Can you use these study amounts yourself?

No. Retatrutide isn't approved, so it has no standard dose. This page only tells you what study doctors gave people under close care. Those figures can't set your dose. The numbers come from the first small test of safety ^[4], a Phase 2 obesity study ^[1], and Phase 2 work with adults who had type 2 diabetes ^[2]. Doctors chose each amount and watched for harm. On your own, you wouldn't have that safety net.

What retatrutide dosage did the studies test?

First small type 2 diabetes test: Five groups got 0.5 mg, 1.5 mg, 3 mg, 3/6 mg, or 3/6/9/12 mg. Doctors gave the under-the-skin shot each week for 12 weeks ^[4]. They raised the amount bit by bit and watched what people could bear.

Phase 2 obesity study: Four groups worked up to 1, 4, 8, or 12 mg. Each person received the under-the-skin shot weekly for 48 weeks ^[1]. Starting with less was meant to ease stomach trouble.

Phase 2 type 2 diabetes study: The weekly amount rose from 0.5 mg to no more than 12 mg. Final amounts were 1, 4, 8, and 12 mg ^[2]. Doctors cut some insulin as blood sugar improved.

Phase 3 studies: The study called TRIUMPH-1 and other large final tests use the same kind of shot each week. Full details weren't public by mid-2026 ^{[7][8][9][10]}. None of these facts tells you what amount would be safe for you. You'd still need your doctor to decide what fits you.

What does retatrutide half life tell you?

It tells you the drug leaves your body slowly. The first small test found a six-day wait cleared half the drug ^[4]. Retatrutide has a small fat-like tail that slows its clearing from the blood. That slow exit explains the weekly shots. After three to four weeks, a new shot may add to drug still in your body. Here's the catch: a fast pulse or stomach trouble may last for days. You can't switch the drug off at once.

Which retatrutide side effects made people stop?

In the Phase 2 obesity study, up to 45 percent had nausea at 12 mg. Constipation, diarrhea, and vomiting also occurred ^[1]. Most trouble was mild or fair. Higher amounts caused more of it. Doctors started with less, then raised it bit by bit. Even so, side effects made 18 percent of the 12 mg group quit ^[1].

At the top amounts, resting pulse rose about 5–7 beats a minute. Week 24 brought the biggest rise ^[1]. About 8 percent had a skin problem at the shot spot. Grave low blood sugar didn't occur in people not using insulin or certain diabetes pills. In the Phase 2 diabetes study, mild or fair gut trouble affected 35 percent. There were no deaths. Grave low blood sugar didn't occur ^[2]. Days of stomach trouble could cost you food, water, sleep, work, and strength. Your own cost may matter more than the average.

How to reconstitute retatrutide, or mix its powder?

There aren't any approved mixing directions. To reconstitute means to add liquid to powder for a shot. The studies didn't do that. Eli Lilly supplied retatrutide already mixed as a liquid, and study staff gave the weekly shot. No approved product exists outside those studies.

Online powder could contain another drug or germs. The published studies used only liquid made for the study ^[1][4]. They give no safe way to mix, store, or prepare online powder. We don't print steps for making an unapproved shot. Perfect steps still couldn't reveal the vial's contents.

Is there a real retatrutide cost yet?

There isn't an approved store price. Retatrutide isn't for sale as a tested drug. People in studies get it at no cost as part of the study. Sellers outside pharmacies and approved studies set their own prices for powder marked "for research only." A price can't tell you what's in that vial or whether it's clean.

A 2024 medical article gave no price because retatrutide hadn't reached the sale stage ^[14]. Claims on seller pages can't change that. You'd be paying for material whose name, strength, and lack of germs can't be proved from a sales page.

Retatrutide vs tirzepatide: do we know which is better?

No. Tirzepatide is approved for type 2 diabetes and obesity. It copies the hunger-and-sugar hormone called GLP-1 and one other hormone job. Retatrutide also copies GLP-1, then adds a third job that may raise energy use. Retatrutide isn't approved.

Separate Phase 2 studies found about 15–21 percent weight loss at the highest tirzepatide amounts. Retatrutide's Phase 2 study found 24.2 percent at 48 weeks ^[1]. That isn't a fair contest. The people, timing, and rise in amounts differed. You can't call one better from two separate studies.

One ongoing study puts the two drugs head to head. It hasn't reported results ^[10]. Researchers think retatrutide's third hormone job may burn more energy. That idea doesn't prove better results ^[1][6].

When will retatrutide be available, if it passes?

The maker hasn't named a date. Phase 3, the last large test round, often takes 18 to 36 months. Phase 3 must end first. The maker then sorts the findings, sends the FDA a request, and waits. A usual review may last 6–12 months. A faster review is possible, but approval isn't promised. No request had been announced by mid-2026. The retatrutide availability page shows each step left for you to watch. You can track the steps without making a guess part of your plan.